Stocks · Health care · Pharmaceutical Preparations

Sagimet Biosciences Inc.

SGMT Clue Score32
United States Fiscal year ends December CIK 0001400118 Results filed 11 Aug 2026

What the insiders did Net selling

By person

5 insiders · 10 transactions
12.0×

David Happel holds 12.0 times base salary in stock. $7.59M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what David Happel last reported holding, valued at $10.23, the price Series A Common Stock was last bought or sold at on the open market here, on 14 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
George Kemble
Director
—
$4.22M (4) scheduled
−$4.22M
62,161
0.117%
$636.08K
−47.6%
David Happel
President & CEO
—
$561.93K (2)
−$561.93K
741,570
1.4%
$7.59M
+16.0%
Elizabeth Rozek
Chief Legal & Admin. Officer
—
$95.89K (2)
−$95.89K
224,414
0.423%
$2.30M
+39.8%
Eduardo Bruno Martins
Chief Medical Officer
—
$19.51K (1)
−$19.51K
147,296
0.277%
$1.51M
+81.4%
Thierry Chauche
Chief Financial Officer
—
$7.03K (1)
−$7.03K
59,688
0.112%
$610.78K
—